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Abstract 
The main ethical principle in prenatal testing is the autonomous decision of the 
pregnant woman concerned. However, recent developments in prenatal testing 
undermine this model. The overall number of invasive* prenatal examinations has 
dropped significantly. Yet, the amount of pathologic results has increased. Due to 
the improvement in ultrasound diagnostics the predictability of possible disabilities 
or diseases of the unborn child has increased substantially. As a result of this 
pregnant women can take the decision whether or not to undergo invasive prena-
tal examinations on the basis of personal risk "evidence" produced earlier on by 
means of non-invasive* screening. It can be questioned, how autonomous deci-
sions can be if they are increasingly pre-informed through upstream risk-
assessments on the basis of non-invasive screening. Particularly ultrasound 
screening is often carried out without thorough counselling and sometimes even 
without consent. The concept of autonomy is difficult to uphold if women do not 
deliberately decide whether to undergo non-invasive screening, but the moment of 
such a deliberate decision comes only after positive screening results. Taking into 
account that public discourses have rather focused on other aspects of genetic or 
reproductive technologies such as stem cell research or pre-implantation diagnosis 
it is important to analyse how technological innovations transform medical prac-
tices without a re-articulation on a discursive level as I will try to show in this 
paper for the case of prenatal testing.1 
                                                       
* Medical terms are explained in the glossary and marked with a * sign when first used in 
the text. 
1 Acknowledgement: The issues discussed in this paper were investigated in a research 
project called "Prenatal Testing: Individual Decision or Distributed Action" that was carried 
out by the author and his colleagues within the accompanying research programme (ELSA) 
within the Austrian Genome Research Programme (GEN-AU) funded by the Austrian Federal 
Ministry for Education, Science and Culture. 
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1 Introduction 
It is generally assumed that in the 
current medical practice, prenatal 
testing requires genetic counselling*. 
In particular this is true for so called 
invasive (or diagnostic) methods such 
as amniocentesis* and chorionic villus 
sampling (CVS)*. This counselling is to 
secure the individual and autonomous 
decision of the pregnant women 
concerned. It is she and only she who 
should decide matters of prenatal 
testing. Not least for that reason, 
genetic counselling plays a key role in 
prenatal testing and has become an 
obligatory requirement in the proce-
dure. The main task for the counsellor 
is now to give proper information on 
the subject. This is to inform the 
client's decision and to provide medi-
cal knowledge that a pregnant woman 
may not possess. A counsellor will be 
keen to talk about the implications of 
available examinations, possible risks 
they include and their potential out-
comes. Experienced counsellors em-
phasise the importance of stressing 
that prenatal testing is not a guarantee 
for a healthy child and that there are 
certain limits to such examinations 
that anybody who undergoes them 
must be aware of.2 Furthermore, it has 
become a standard that prenatal 
testing will only be performed if a 
pregnant woman has given her explicit 
agreement to the procedure, confirm-
ing that she has received comprehen-
sive information and has decided after 
thorough consideration thereof. 
This framework of prenatal testing 
refers to specific ethical standards, 
which are largely shared among coun-
sellors and physicians in the field (c.f. 
Wertz/Fletcher 1989: 28 and 2004: 36-
43).3 These principles aim to give 
                                                       
2 Based on interview data as conducted by 
the author. 
3 Non-directiveness in genetic counselling 
is a concept that reaches highest accep-
tance among counsellors. In a survey on 
geneticists in 19 nations more than 75% of 
those surveyed agreed to this standard in 
highest priority to the woman's right to 
decide for herself. There are certain 
measures to ensure that all decisions 
are left to the client. Most importantly 
this is through so-called "non-
directiveness" in counselling. In short 
this means that the physician should 
serve as an informant, but must not 
influence or prejudge decisions in one 
way or another. This way "informed 
consent"* should be achieved. All 
together: "The counsellor-client rela-
tionship is based on values of care and 
respect for the client's autonomy, 
identity, welfare and freedom" (NSGC 
1991). 
It has been argued elsewhere (c.f. 
Clarke 1991: 1000; Marini et al. 2002: 
171; Wertz/Fletcher 2004: 38) that in 
practice it is not so easy to actually 
come close to this ideal. But despite all 
the difficulties in applying these ethical 
standards, they still remain the domi-
nant reference point for physicians and 
counsellors in prenatal testing. How-
ever, some have taken a critical view of 
the underlying individualism. Elisabeth 
Beck-Gernsheim for example has 
argued that the opportunity to decide 
is also an obligation to do so. In fact 
the possibility to not decide no longer 
exists (Beck-Gernsheim 1990: 157; 
Beck 1990: 52). A personal decision 
becomes inescapable. But, whoever 
decides is responsible for what follows 
from that decision. It can be argued 
that there is a specific coupling be-
tween individual decision and personal 
responsibility. 
Undoubtedly the guiding vision of an 
"autonomous decision" in prenatal 
testing is a powerful driving force that 
shapes clinical practice to the present 
day. However, in this article I will 
                                                                 
more than 75% of the investigated coun-
tries (c.f. Wertz/Fletcher 1989: 28). Having 
investigated 36 nations in 1993-95 Wertz 
and Fletcher point to the fact that "unbi-
ased information" is a guiding norm for 
English-speaking nations in particular and 
similarly important for northern and 
western European countries (c.f. 
Wertz/Fletcher 2004: 36-43). 
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argue that medical practice is not 
exclusively a matter of social construc-
tions. In particular I will question how 
independent such a decision or in-
formed consent actually is. For that 
reason it is the role of the medical 
technologies that is examined more 
carefully. To what extent do the testing 
methods applied exercise an influence 
on prenatal testing? In providing an 
answer to this question it can be 
shown how technological innovations 
contribute to the re-organization of 
medical practices. 
 
2 Methodology 
The argument presented in this paper 
is based on an empirical study carried 
out by the author and his colleagues. 
The study aims to examine the individ-
ual character of decisions in the 
course of prenatal testing and focuses 
on processes that contribute to an 
individualization of responsibility for 
decisions in the context of prenatal 
examinations. Among other research 
methods we have carried out expert 
interviews with physicians (geneticists 
and gynaecologists) who perform 
prenatal testing. 
Purposive sampling was used to obtain 
a sample of 15 experts in prenatal 
testing. We have chosen interviewees 
who work in the major centres for 
prenatal testing in Austria. With one 
exception we could carry out inter-
views with physicians from all the 
centres for prenatal testing who run a 
cytogenetic* laboratory. In addition we 
interviewed physicians from a province 
which does not have a cytogenetic 
laboratory on its own, but send there 
samples elsewhere for analysis. One 
geneticist was interviewed who does 
not carry out prenatal testing anymore, 
but has done so previously. Ten of our 
interviewees are gynaecologists who 
carry out the prenatal tests in co-
operation with one of the cytogenetic 
laboratories or have one in their own 
department. 
Semi-structured guideline based 
interviews were carried out by mem-
bers of the research team and were 
audio-taped and transcribed. The 
interviews were carried out in the 
offices of the interviewees and were 
typically one to one hour and a half 
long. All interviewees were informed 
about the purpose of the interview and 
asked for consent to using the material 
for our study. For the qualitative 
analysis we used a software for data 
management and analysis (atlas.ti). 
In the course of the interviews our 
interviewees provided us with data of 
the tests they have performed. In this 
paper I will analyse these data on the 
frequency of the tests, the indications* 
they were induced, and the number of 
positive results. The analysis is in-
formed by the expertise of the inter-
viewees who explained the data to the 
interviewer. However, it needs to be 
mentioned that there are no consistent 
data on the total number of prenatal 
tests on a national level. Data are only 
available from the centres which offer 
such tests and willing to open up to 
social scientists. The figures presented 
in this paper are data of a particular 
centre, which can be regarded as a 
typical case. The centre is of national 
importance and one of the largest in 
the country. Our interviewees of the 
other centres observe a similar picture 
in their own context and confirm the 
trend we present here in the interviews 
we have taken. On this basis it is 
claimed that the presented findings 
give an appropriate account of prena-
tal testing in Austria. 
The developments described in this 
paper can also be observed in other 
countries (e.g. Wray et al. 2005, 
Benn/Fang/Egan 2005 for the USA). 
However, it is difficult to generalize the 
practice of prenatal testing. The na-
tional health care systems are different 
and they provide different circum-
stances for antenatal care accordingly. 
Diffusion patterns of medical tech-
nologies vary from one country to 
another and also legal frameworks are 
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unlike to name a few parameters, 
which make it difficult to compare or 
even generalize. For that reason this 
paper does only claim to provide an 
analysis for Austria. On the other 
hand, medical science is highly inter-
nationalised and medical technologies 
are commercialised on a global mar-
ket. Several of the Austrian specialists 
in prenatal testing have worked in 
other countries and learned from their 
colleagues abroad. For that reason 
developments in prenatal testing take 
place on an international scale, but 
they are situated in specific national or 
even regional contexts. This paper will 
bring together both dimensions and 
thereby exemplary show how interna-
tional developments in diagnostic 
technologies are integrated in a na-
tional medical practice. 
 
 
3 Medical background on the 
developments of testing meth-
ods 
During the last ten years, quite a 
remarkable development can be ob-
served in prenatal testing. The overall 
number of prenatal testing by means 
of amniocentesis and CVS is declining 
dramatically. In certain Austrian hospi-
tals the total number has decreased by 
one third of its peak in 1995. Geneti-
cists report that in Germany a decline 
of 50 percent can be observed4 and a 
recent studies refers to a similar 
change in the USA (c.f. Wray et al. 
2005: 353; Benn/Fang/Egan 2005: 328, 
Benn et al. 2004). In order to offer an 
explanation for the dramatic change in 
the frequency of invasive prenatal 
testing it is argued that the medical 
technologies applied play a major role. 
Decisions of pregnant women and 
                                                       
4 Based on interview data as conducted by 
the author. 
Figure 1 - Total number of invasive prenatal tests 
 
 
Total: total number of all women who have undergone invasive prenatal tests (accord-
ing to various indications). 
Maternal age: tested women of advanced age 
Rest together: tested women of all other indications 
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related counselling processes cannot 
be understood appropriately if tech-
nologies and the medical data they 
produce are seen as neutral or even 
negligible as an influence. 
Taking a closer look on the diagram 
above (figure 1)5, it becomes obvious 
that the dynamic of the total number 
of invasive prenatal testing is deter-
mined chiefly by just one factor: ma-
ternal age. Any test has a justification 
why it is undertaken and if the justifi-
cation is "only" that a particular 
woman wants to have it. But most of 
the time there is a medical justifica-
tion, i.e. a higher risk of foetal anoma-
lies compared with that on average. If 
this is the case and there actually is 
such a higher risk, in medical terms 
this is called an "indication". For 
example a prenatal test could be 
indicated because a woman has previ-
ously given birth to a disabled child. 
Yet, in most cases the indication for a 
subsequent prenatal test is maternal 
                                                       
5 The figures refer to empirical data from a 
specific clinic, which remains anonymous 
here. 
age. Women of 35 years and older 
show a higher risk of chromosome 
aberrations* (trisomies* or transloca-
tions*). As one can see from the dia-
gram above (figure 1) up to three 
quarters of all invasive prenatal tests 
have been undertaken for that very 
reason (between 1978 and 2003 the 
ratio did not drop below 68% and 
reached its peak in 2001 at 77.6% in 
the presented case). Advanced mater-
nal age is regarded as an indicator 
because of the correlation as described 
here: "Generally the probability of a 
birth of a child with Down's syndrome 
(and many other chromosome anoma-
lies) increases with the age of the 
mother. The so-called age indication 
following from the fact that this is the 
most frequent reason for a prenatal 
chromosome analysis" (Sancken et al. 
2003, my translation). A diagram 
(figure 2) shows the correlation be-
tween birth giving age of the mother 
and a higher rate of chromosome 
aberration; trisomy 21 in this case. 
Generally it is true that women of 
advanced maternal age do have a 
higher risk. But for some reason this 
Figure 2 - Maternal age and trisomy 21 
Source: Snijders et al. (1999:169)
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correlation no longer plays such a 
significant role in the management of 
antenatal care. Advanced maternal age 
is not indicating an invasive prenatal 
test to the extent that it did only a few 
years ago. This becomes clear when 
considering the dramatic decline in the 
number of examinations indicated by 
advanced maternal age. At this point 
the question arises: why is that the 
case? 
The first point to mention is that, if age 
is the chief indicator for a higher risk, 
many pregnant women will be tested. 
In Austria the proportion of women 
who are of advanced age (35 years and 
older) and give birth to a child is 15% 
(Statistik Austria 2004: 68).6 This 
equates to 11,856 women in the whole 
country in 2002. However, even if, 
theoretically, all pregnant women of 
advanced age would be tested, the 
                                                       
6 Only in 1981 the proportion of women 
giving birth to a child at the age of 35 or 
older was 6,4%; a total of 6.016 women 
(Statistik Austria 2004: 68). According to a 
recent publication in Germany the propor-
tion of pregnant women of advanced 
maternal age is about 13%" (c.f. Sancken et 
al. 2003). 
majority of trisomy 21 pregnancies will 
not be detected that way. This argu-
ment was already made at the time 
when maternal age was sharply on the 
rise. Wald et al. explained that "in 
practice fewer than 15% of affected 
pregnancies are detected because 
fewer than half of these older women 
actually have amniocentesis" (Wald et 
al. 1988: 883).7 
Equally Saller and Canick pointed out 
in the mid 1990s, when age indication 
reached its peak: "by only offering 
amniocentesis to women older than 
age 35 only approximately 20% of 
foetal Down's syndrome will be de-
tected" in practice, and furthermore 
they conclude: "This approach results 
in failure to detect the approximately 
80% of babies with Down syndrome 
born to women younger than age 35." 
(Saller/Canick 1996: 784) Meanwhile 
the proportion of women who have 
babies at a later stage of their life has 
increased. Consequently the percent-
age of possible detection* with age as 
                                                       
7 This has been claimed for the UK where 
5% of women are aged 36 or greater when 
being pregnant (Wald et al. 1988: 883).  
Figure 3 - Chromosome aberration in relation to invasive prenatal tests per-
formed 
Pathologic results with chromosome aberration in percent of all women tested with
invasive methods. 
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an indicator has increased and is 
estimated at about 30 to 40 percent if 
all women 35 and older would be 
tested (c.f. Sancken et al. 2003). De-
spite the fact that maternal age has 
increased on average the majority of 
trisomy 21 pregnancies are still con-
ceived by women younger than 35. 
Some have concluded on the basis of 
this that "with regard to the total 
population of pregnant women age 
indication is neither particularly sensi-
tive nor very specific" (Sancken et al. 
2003). In short, from a medical point 
of view maternal age is an indicator, 
but it is not a very good one. One 
could even say that it is not much 
more than a qualified guess that about 
four out of a thousand 35 year old 
pregnant women are carrying foetuses 
with Down's syndrome. 
Following the described logic a more 
accurate indicator than maternal age is 
desirable. The point now is, that 
meanwhile there are better indicators 
that help to identify for an amniocen-
tesis or CVS those women who have 
more reasons to undergo such exami-
nations than simply being of advanced 
age.  
When looking at the data one can 
observe that even though the total 
number of invasive prenatal tests has 
gone down by about 40%, the number 
of foetuses diagnosed with chromo-
some aberration is still going up.8 
Figure 39 shows how significant this 
development is by relating the number 
of test results with chromosome 
aberrations to performed examina-
tions. If this development is a result of 
the availability of better indicators, so 
what are these better indicators? The 
answer to this question is: non-
invasive prenatal testing is a better 
                                                       
8 46 chromosome aberrations out of 1067 
tested women of age indication in 2000; 76 
chromosome aberrations out 771 tested 
women of age indication of 2003. 
9 The figures refer to empirical data from a 
specific clinic, which remains anonymous 
here. 
indicator for subsequent invasive 
examinations than simply maternal 
age alone. 
Historically it was the so-called triple-
test* that first provided a better 
judgement of the likelihood that a 
foetus would show anomalies. The 
problem with this triple-test is that it 
produces a relatively high number of 
false results as Babbur et al. point out 
in a recent publication: "For the 
screened population, to achieve an 
88% detection rate using the triple test 
alone, the predicted FPR [false-positive 
rate*] would be 20%. Conversely, for 
an FPR of 4,8% using the triple test 
alone, the detection rate would be only 
60%" (Babbur et al. 2005: 465). For 
that reason, the triple-test was contro-
versial among physicians, and some 
Austrian hospitals decided not to use it 
any longer. 
Also in the literature the triple-test is 
contested: "The original age indication 
limiting prenatal diagnosis to women 
over 35 has now largely disappeared in 
practice, so that every pregnant 
woman is notified of the possibility of 
PD [prenatal diagnosis] by her gynae-
cologist. The expansion of the use of 
PD has been driven by the so-called 
'triple test', which makes it possible to 
identify an increased risk of chromo-
somal anomalies in a foetus from an 
examination of the mother's blood. 
Although this test is under severe 
criticism from human geneticists for its 
lack of validation and frequent false 
positive (and negative) results, it is 
offered by many gynaecologists as a 
'safety first' test, which is often fol-
lowed by a (frequently unnecessary) 
amniocentesis" (Hennen et al. 2000: 
9).10 
At first maternal serum* screening was 
offered as an alternative option for 
those women who did not accept the 
                                                       
10 Translated by the authors in an English 
summary of their working report 
(www.tab.fzk.de/en/projekt/zusammenfas-
sung/ab66.htm; last access 07. Mar. 2006). 
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risk of amniocentesis or CVS. Yet, once 
these tests became available, they also 
gained the function of providing a 
more profound risk assessment for 
those women who wanted to have 
additional information prior to making 
a decision about having amniocentesis 
(c.f. Newberger 2000). Indeed maternal 
serum screening is still advocated as a 
useful means to reduce the number of 
amniocenteses (c.f. Rosen et al. 2002). 
Meanwhile, ultrasound has also be-
come more important, largely due to 
recent improvements. Initially, ultra-
sound was not precise enough to 
detect Down's syndrome foetuses (or 
other chromosome aberrations), but 
this has changed with technological 
advancements in the picture quality. At 
first, ultrasound was used at a later 
stage of the pregnancy and it was used 
for Down's screening only in cases 
where an indication was already given. 
Second-trimester* ultrasound assess-
ment (15-23 weeks) was offered to 
women with increased risk "for trisomy 
21 based on advanced maternal age or 
abnormal maternal serum biochemical 
marker screening, who either had 
declined amniocentesis or chose to 
have a sonogram before deciding 
whether to undergo amniocentesis" 
(Vintzileos et al. 1996: 949). In this 
case ultrasound serves as a second 
step to provide further evidence in an 
already ongoing risk assessment.  
But, there is a tendency to turn this 
upside down. Ultrasound increasingly 
becomes the first step. "Increased fetal 
nuchal translucency is associated with 
chromosomal abnormalities, many 
fetal defects and genetic syndromes" 
(Souka et al. 2001: 9). Ultrasound 
measurement of nuchal translucency* 
is therefore used as a first-trimester 
screening test. Nuchal translucency 
first-trimester screening has a detec-
tion rate of about 76,8% at a false-
positive rate of 4,2% (c.f. Krampl 2005: 
86). In other words, three quarters of 
all foetuses with trisomy 21 can be 
identified that way, but this rate can be 
increased if other biochemical tests are 
performed additionally (called the 
combined test*). Together with an 
analysis of maternal serum (ß-HCG11, 
PAPP A12) the detection is as high as 
87% with a false-positive rate of 5% 
(c.f. Krampl 2005: 86). This can be 
further increased if an ultrasound of 
the nose bone is also performed.13 
Geneticists claim that it can be as high 
as 95 to 97%.14 
Not only are there several alternatives 
in prenatal testing, they are also linked 
together: "Women who are screen-
positive in the first trimester can elect 
to receive cytogenetic testing of a 
chorionic villius biopsy. The first 
trimester test could also, theoretically, 
be combined with the second trimester 
maternal serum screening test (inte-
grated screening) to obtain even 
higher levels of efficacy" (Benn 2002: 
1). 
The point now is that pregnant women 
older than 35 do not need to decide 
whether or not to undergo an amnio-
centesis or CVS just on the basis of an 
anonymous statistical probability. Now 
they can take this decision on the 
basis of personal risk "evidence" pro-
vided by non-invasive testing. And if 
this is the case – that such a non-
invasive screening produces a higher 
risk factor – results of the screening 
would justify a subsequent amniocen-
tesis or CVS. 
Currently there is a trend in invasive 
prenatal testing that such tests are 
performed less often just because of a 
                                                       
11 Human Chorion Gonadotrophin 
12 Pregnancy Associated Plasmaprotein-A 
13 In case the result of an ultrasound 
examination between 11 and 14 weeks is 
the absence of the nasal bone (broad nosal 
bridge syndrome) this is understood to be 
an indicator for foetal abnormalities. 
"Research results indicate that including 
this marker along with the mother's age, 
baby's age, nuchal fold measurement, and 
blood tests can bring the accuracy of the 
risk assessment up to 97 percent." (Baby-
Center 1997-2004b) 
14 According to interview data conducted by 
the author. 
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higher risk due to maternal age (an 
indirect guess based on statistics), but 
increasingly because of a higher risk 
due to risk "evidence" (based on previ-
ous tests). And this is a significant 
difference. Such "evidence" is still no 
proof, but from a medical point of view 
it is a much better risk assessment 
than a "guess" based on maternal age 
alone. The decline of invasive prenatal 
testing indicated by maternal age 
(figure 1) shows how outdated the 
latter has become as an indicator for 
invasive prenatal testing. The observed 
tendency can be related to the in-
creased application of non-invasive 
screening tests. Taken together a shift 
can be observed. This includes a shift 
from maternal age indication to testing 
as a result of prior screening, but a 
series of other changes are evident, 
too. 
1. Increasingly there has already 
been some sort of examination – 
on the basis of which a higher risk 
is determined – before invasive 
testing is carried out. Maternal 
age, on the other hand, is a pre-
sumption without more specific 
empirical evidence for the specific 
case. Now that maternal age has 
lost its importance as an indica-
tion for invasive prenatal testing, 
other indicators have become 
more important. 
2. These other indicators which have 
become more important are pro-
duced by means of non-invasive 
screening methods, mostly ultra-
sonic tests (and the combined ma-
ternal blood test) as already men-
tioned. And because non-invasive 
tests have become more important 
and more reliable, the total num-
ber of amniocentesis and CVS has 
gone down dramatically. 
"For many years, research on ma-
ternal blood tests has been per-
formed. A tendency towards pre-
selection on the basis of non-
invasive methods can be noted. 
This way, an earlier start, higher 
effectiveness and higher accep-
tance can be achieved as well as a 
distribution of prenatal testing 
across all stages of age" (Ar-
beitsstelle Pränataldiagnostik/Re-
produktionsmedizin 2004). 
3. As mentioned in the previous 
quote, the current shift in prenatal 
testing represents also a shift to-
wards testing at a much earlier 
stage, from second to first trimes-
ter of the pregnancy. Time is in 
fact a major factor in prenatal test-
ing and many have argued (c.f. 
Katz-Rothman 1989) that the ear-
lier the testing the better it will be. 
Not only does the time a women 
has to wait for the result matter 
(which is a major disadvantage of 
amniocentesis), but also the ad-
vancement in the pregnancy 
makes a difference. If an abortion 
is to be considered, this is easier 
to cope with before the 24 week of 
the pregnancy when a curettage* 
can still be performed. 
4. The tendency is noted that non-
invasive techniques lead to an ex-
pansion in prenatal testing. A 
growth in participation can be 
concluded since the number of in-
vasive tests has gone down but the 
number of pathologic results has 
increased significantly at the same 
time (see figure 3.). Most likely this 
is explained by more young 
women deciding in favour of a 
non-invasive screening. 
5. Another reason for the expansion 
of prenatal testing can also be re-
lated to the fact that invasive tests 
require a specialized laboratory 
that is able to carry out the analy-
sis. In Austria there are only a few 
of such laboratories.15 Non-
invasive techniques, however, al-
ready have a much higher dis-
                                                       
15 In fact the common practice in invasive 
testing is that the sample was taken not 
only in clinics which had a cytogenetic 
laboratory. Those who did not have a 
laboratory on their own would send it to 
one of these institutions for the analysis. 
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semination and can be performed 
in a number of clinics. 
6. Non-invasive screening tests also 
lead to "inescapable decisions". 
Generally, all couples are at risk of 
conceiving a child with chromo-
some aberrations or other anoma-
lies, but a statistical probability 
does not tell who will and who will 
not. Advanced maternal age is a 
hint that the probability increases 
with age, but it does not tell who 
will actually give birth to a child 
with chromosomal anomalies. 
Only an invasive test can answer 
this question. But now non-
invasive screenings provide an in-
dividual risk figure. By these 
means, decisions are increasingly 
taken on the basis of individually 
determined risk and not any 
longer on an anonymous statisti-
cal correlation, which could dis-
tinguish a certain age group at 
best. In this sense, one could say 
that invasive tests have become 
more medicalized, because deci-
sions no longer start from zero. 
7. Finally a last shift can be noted. 
The decision-making process is di-
vided into a number of small deci-
sions. There is no such thing as 
"one" decision, where everything is 
decided at once. In other words, 
decisions are by no means a-
priori, i.e. without pre-conditions. 
On the contrary, decisions are 
taken step by step with one lead-
ing to another: first the individual 
risk is determined, then a definite 
diagnosis is produced and only 
then does the question arise about 
whether or not to abort the preg-
nancy. 
As the presented data show the shift 
described has only come about only 
recently. In the second half of the 
1990s a stagnation of performed 
invasive prenatal tests can be noted. 
However, that this development would 
turn into a decline became clear only 
after 2001 when tests induced by age 
indication significantly dropped. 
Obviously the technologies which have 
lead to the mentioned changes in 
prenatal medicine have been devel-
oped several years earlier. Nuchal 
translucency measurement was devel-
oped in the 1990s and combined with 
maternal serum markers thereafter (c.f. 
Nicolaides et al. 1992; Brizot et al. 
1994). Until the innovation could 
exercise its full impact in Austria, 
physicians had to be trained (in Lon-
don at King's College), but also the 
knowledge about the existence of the 
new method and who is able to per-
form it had to be communicated. 
Furthermore it takes some time to 
change the regime of antenatal care in 
which pregnant women are informed 
about diagnostic possibilities and 
referred to respective specialists. 
However, meanwhile the shift has 
become evident. One of our interview-
ees explained that they have a partici-
pation rate of 99% of all women who 
give birth in their hospital. A physician 
from a centre in another province of 
the country said: Yes, we offer non-
invasive screening to all pregnant 
women. They only come to me after 
the screen. And from a third centre for 
prenatal testing we know that the 
number of chromosome aberrations 
diagnosed (with invasive methods) has 
doubled since 2000. This means that 
also the number of tested women has 
at least doubled taking into account 
that more and more young women are 
screened with nuchal translucensy 
measurement. Although comprehen-
sive data of the entire country on the 
participation of pregnant women in 
antenatal screening programmes are 
not available there is clear evidence for 
a substantial diffusion of non-invasive 
screening methods. 
4 Discussion 
It is argued that the observed shift in 
prenatal testing leads to an individu-
alization process. From a medical 
point of view it might be desirable to 
have a more accurate risk assessment, 
which allows for a better management 
of invasive prenatal testing (decisions 
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seem to be evidence based and there-
fore more rational). But on the other 
hand the determination of an individ-
ual risk can also be seen from a socio-
logical point of view. 
The notion individualization was 
prominently introduced by Ulrich Beck 
in his book "Die Risikogesellschaft" 
(Beck 1986) and Elisabeth Beck-
Gernsheim (1990) has discussed indi-
vidualization in the context of repro-
duction. Already when the concept was 
introduced it was argued that indi-
vidualization does not only lead to an 
increased freedom of choice, but that it 
would also lead to a pressure to take 
decisions. Furthermore Beck argued 
that individualization is paradoxical 
and includes what he has called "con-
trol" or "reintegration dimension" 
(1992: 128). From this point of view 
prenatal testing means the integration 
of pregnant women into a control 
regime. Indeed, with the expansion of 
ultrasound screening more and more 
pregnant women are integrated into a 
medical network, which determines 
their individual risk for foetal anoma-
lies. In his Book "Discipline and Pun-
ish" (1975) the French philosopher 
Michel Foucault has defined individu-
alization as the identifiability of the 
individual. Following this understand-
ing of individualization it can be ar-
gued that the prenatal regime aims to 
differentiate pregnant women and this 
differentiation is predominantly carried 
out in terms of risk. The place they are 
allocated to is derived from a sophisti-
cated risk-assessment. 
Nevertheless, this does certainly not 
mean that pregnant women are not 
free to decide. It is essential for prena-
tal testing that it is the women con-
cerned who decide about their own 
pregnancies. This results in a funda-
mental paradox: There are more and 
more possible decisions, but these 
possibilities are produced in a system-
atic way. Thomas Lemke has argued 
that decisions become increasingly 
choices between options, but the 
options are pre-given beforehand and 
structured by pre-decisions (c.f. Lemke 
2000: 243). It is increasingly impossi-
ble not to choose because it is harder 
and harder to escape the risk assess-
ment by means of ultrasound screen-
ing. Choices promise freedom, but the 
confrontation with one's individual 
risk demands a decision which takes 
the screening results into account. 
Whether a chromosome anomaly is 
actually given or not can only be 
clarified through an invasive diagnos-
tic step (cytogenetic methods are not 
based on statistical methods, but they 
provide definite results at a very low 
rate of false results). However, such 
invasive tests are bound to a risk of 
miscarriage (c.f. Evans/Wapner 2005). 
For this reason many women want to 
avoid an invasive examination. But as 
it has been argued in this paper such 
decisions whether or not to undergo 
an amniocentesis or CVS are increas-
ingly bound to an upstream risk as-
sessment. Hence these decisions are 
not taken without conditions, they are 
taken under consideration of medically 
generated data. 
The point now is that these risk-data 
are produced in a framework which 
substantially differs from invasive 
testing. Our interviews suggest that 
increasingly genetic counselling is only 
performed in cases of positive screen-
ing results (prior to invasive testing). 
Decision autonomy is still the central 
ethical orientation in prenatal testing, 
but the consent procedure prior to 
non-invasive screening is largely 
formalized and often women don't 
realize the significance of the examina-
tion. Women are still asked to decide 
and they are explained that it is their 
own personal decision, but the mo-
ment of such a deliberate decision 
comes only after positive screening 
results. It is questionable if such 
decisions can be accounted "autono-
mous" if they are taken against the 
backdrop of a risk-assessment pro-
duced by medical examinations. 
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Apparently the described technological 
transformation in prenatal testing goes 
along with significant changes in the 
practice of its application. However, 
the assumption that "technical change 
causes social change" is usually la-
belled as technological determinism 
(MacKenzie/Wajcman 1985: 5). Günter 
Ropohl talks about "consequential 
technological determinism" (1991: 
193). The criticism is, that technology 
is nothing original, but technology 
itself is socially created. 
Nevertheless, one may ask, why it is 
possible to carry out non-invasive 
testing in a different organizational 
framework than invasive testing: Why 
is it possible for gynaecologists to 
perform nuchal translucency meas-
urement without thorough conversa-
tion about the significance of the 
examination, whereas geneticists still 
insist on profound genetic counselling 
prior to amniocentesis? Both test 
methods are predictive malformation 
diagnostics. Thus the differences in the 
practice of their application require an 
explanation. 
The risk of miscarriage caused by the 
examination is a substantial difference 
between invasive and non-invasive 
testing that can be related to the 
technology. Bettelheim et al. specify 
the risk of miscarriage (including 
intrauterine foetal death) to be 0.44 for 
Amniocentesis and 0.99% for CVS 
(2002: 119). Not least for liability 
reasons an essential task of the coun-
selling interview is to inform the 
pregnant women about the risks and 
limitations of the examinations them-
selves. But if the risk that the per-
formed examination may cause a 
miscarriage can be precluded there is 
no need to seek for "informed consent" 
for that reason. 
There are certainly more reasons for 
counselling prior to prenatal testing. 
Doubtlessly the ethical model of deci-
sion autonomy needs to be understood 
in its historical context, namely as a 
possibility to overcome classical 
eugenics and the catastrophe of Na-
zism. Nevertheless, against the back-
drop of the changes in the current 
practice of prenatal testing, it is also 
important not to disregard the efficacy 
of the technology applied. 
 
5 Conclusion 
The aim of this paper was to highlight 
the significance of the emergence of 
new prenatal screening technologies 
and to show their impact on medical 
practices. The role these screening 
technologies play, becomes evident 
when relating their development and 
dissemination to the frequency of the 
total number of invasive prenatal tests. 
By emphasising the role of technology 
the question arises: how autonomous 
can a decision be? To what extent can 
a decision about whether or not to 
have amniocentesis (or CVS) be re-
garded as autonomous if it is taken on 
the basis of previous risk assessments 
determined by screening. The concept 
of autonomy is difficult to uphold if 
diagnostic technologies apparently 
have such a strong impact. 
The decision about whether or not to 
undergo invasive tests increasingly 
depends on medical evidence. Such 
medical evidence is produced from the 
first moment a woman learns about 
her pregnancy. It is largely through 
improvements in ultrasound screening 
and other non-invasive tests that 
maternal age loses its importance as 
the chief indicator for an invasive test. 
The corresponding decline of amnio-
centeses or CVS shows that non-
invasive screening methods serve as a 
means of risk assessment further 
upstream. But it is not only pregnant 
women of advanced age who can now 
decide on the basis of a previous risk 
assessment. More and more pregnant 
women undergo such a "pre-test" in 
screening programmes. It has been 
argued that the new diagnostic tech-
nologies contribute to an expansion of 
prenatal testing even though invasive 
tests are performed less frequent. This 
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way the character of prenatal testing 
becomes quite different; it can be 
argued that ultrasound changes the 
function of invasive tests. Amniocente-
ses and CVS are increasingly carried 
out to confirm a qualified suspicion 
produced by a risk assessment up-
stream. 
In the introductory section of this 
paper it was stated that the highest 
priority is given to the autonomy of the 
patient, and that the goal of counsel-
ling is to ensure this for individual 
decision made by pregnant women. 
Having argued that decisions are 
increasingly "pre-informed" through 
upstream risk assessments on the 
basis of non-invasive screening, the 
question arises as to how patient 
autonomy and individual decisions go 
together with current developments in 
prenatal testing. Is the philosophical 
concept of an autonomous subject still 
appropriate for the problem at stake, 
and if not, are there alternatives? What 
does all of this mean for the concept of 
informed consent? And last but not 
least, what does the current develop-
ment mean for counselling practices? 
As a matter of fact there is not much 
counselling involved prior to ultra-
sound or maternal serum screening. In 
many European countries prenatal 
screening is offered routinely,16 but 
increasingly genetic counselling is only 
performed in cases of positive screen-
ing results (prior to invasive tests). The 
practice of prenatal testing has 
changed considerably since such new 
screening methods as described above 
are available. Despite its significance 
this transformation has not received 
much public recognition in Austria to 
this point. Public discourses have 
rather focused on other aspects of 
genetic or reproductive technologies 
such as stem cell research, human 
cloning or pre-implantation diagnosis. 
Taking this into account it is even 
more important to analyse how tech-
                                                       
16 A remarkable exception to this rule are 
the Netherlands. 
nological innovations transform medi-
cal practices without a re-articulation 
on a discursive level as it was tried to 
show in this paper for the case of 
prenatal testing. 
 
6 Glossary 
Aberration (chromosomal): the medical 
term for an abnormal set of 
chromosomes. Humans have 46 
chromosomes in each cell. Too many or 
to few chromosomes in the cells are 
associated with particular disabilities 
and diseases. This is also the case if the 
chromosomes are damaged, a piece is 
missing or to much in the set of 
chromosomes. See also chromosome, 
translocation, and trisomy. 
Amniocentesis: a diagnostic test, usually 
carried out between 14 - 17 weeks of 
pregnancy, in which a needle is 
inserted through the abdomen to 
remove a sample of amniotic fluid 
containing cells from the developing 
baby for testing. Either the 
chromosomes of the cells are examined 
for prenatal diagnosis of genetic 
abnormality or DNA is prepared for 
analysis. Ultrasound is used to guide 
the needle. The procedure carries a risk 
of miscarriage of about 0.5%. 
Chorionic villus sampling (CVS): a 
diagnostic test normally performed 
between 9 - 11 weeks of pregnancy. A 
needle is inserted through the mother's 
abdomen or cervix and is used to 
remove a small amount of placental 
tissue (afterbirth). Foetal chromosomes 
or DNA can then be examined similar to 
amniocentesis. The procedure carries a 
risk of miscarriage of about 1%. 
Chromosome: a piece of densely packed 
DNA containing hereditary information 
of the organism. See also aberration, 
translocation, and trisomy. 
Combinet test: a non-invasive screening 
method, which combines nuchal 
translucency measurement and 
maternal serum test. In such a way the 
predictability of chromosomal 
anomalies can be increased up to 87%. 
If an ultrasound of the nose bone is 
also performed, the predictability can 
be further increased to 95-97%. 
Curettage: a surgical abortion refers to the 
procedure performed by a doctor to 
remove the pregnancy from the uterus. 
In early pregnancy the surgical abortion 
is called a vacuum aspiration or a 
suction curettage.   
Cytogenetics (cytogenetic testing): the 
study of the structure, function, and 
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abnormalities of human chromosomes 
and chromosomal anomalies. For 
prenatal testing a sample of foetal cells 
is required, gained either by 
amniocentesis or chorionic villus 
sampling (CVS). 
Detection (rate): it is not possible to 
identify all chromosome anomalies 
with non-invasive screening methods. 
The detection rate indicates the ratio of 
the cases that are identified by means 
of a particular test in relation to all 
cases that are actually given. 
False negative: test results which suggest 
that a foetus does not have a condition 
which it later turns out to have. 
False positive: test results which suggest 
that a foetus has a condition which it 
later turns out not to have. 
Genetic counselling: A process by which 
information is imparted to those 
affected by or at risk of a genetic 
disorder. It includes information on the 
nature of the disorder, the size and 
extent of genetic risks, the options, 
including genetic testing, that may help 
clarify the risks, and the available 
preventative, supportive and 
therapeutic measures. In the context of 
genetic testing it may include 
responding to the concerns of 
individuals referred and their families, 
discussing the consequences of a test, 
and help choose the optimal decision 
for themselves, but not determining a 
particular course of action. 
Indication: the reason or justification for 
carrying out a diagnostic or therapeutic 
measure. 
Informed consent: permission given by an 
individual to proceed with a specific 
test or procedure, with an 
understanding of the risks, benefits, 
limitations, and potential implications 
of the procedure itself and its results. 
Invasive methods: amniocentesis, 
chorionic villus sampling (CVS) or other 
procedures to take a sample of foetal 
cells. Such invasive methods of sample 
taking are necessary for diagnostic 
testing, i.e. the analysis of the 
chromosomes or sequences of the DNA. 
Maternal serum: refers to maternal blood 
in the context of prenatal testing. 
"Maternal Serum (Screening) Tests" are 
blood tests performed to determine the 
risk of foetal anomalies (such as neural 
tube defects and chromosomal 
anomalies). The calculation is based on 
the levels of alpha-fetoprotein, estriol, 
and human chorionic gonadotropin in 
the mother's blood during pregnancy. 
These indicators can be measured 
alone (triple test) or together with a 
nuchal translucency measurement 
(combined test). 
Neural tube: a structure in early foetal life 
that develops into the brain, spinal 
cord, spinal nerves and spine. Defects 
of the neural tube are severe conditions 
and sometimes lethal. To the present 
knowledge, they are not genetic, 
although it is assumed that they might 
be. 
Non-invasive methods: ultrasound 
examinations or maternal serum tests 
where no foetal cells are taken. Such 
non-invasive methods allow for 
probabilistic tests in order to determine 
the risk of foetal anomalies (such as 
neural tube defects and chromosomal 
anomalies). This form of prenatal 
testing is also referred to as screening. 
See also maternal serum and nuchal 
translucency measurement. 
Nuchal translucency (measurement): the 
nuchal translucency test is used to 
determine if a woman is at high risk of 
having a baby with a chromosomal 
anomaly.  
Translocation: an anomaly, which has 
moved one piece of a chromosome to a 
different position. Translocations can 
be balanced (the set of chromosomes is 
complete, but does not have the proper 
form) or unbalanced (a piece of a 
chromosome is missing or too much in 
the set of chromosomes). 
Trimester (first, second or third): any of the 
three 3-month periods into which 
pregnancy is divided. 
Triple test: a maternal serum test used to 
determine the risk of foetal anomalies 
(such as neural tube defects and 
chromosomal anomalies). The 
calculation is based on the levels of 
alpha-fetoprotein, estriol, and human 
chorionic gonadotropin in the mother's 
blood during pregnancy. Also called 
"Multiple Marker Test".  
Trisomy: three copies of a single 
chromosome in the cells. The most 
common form is trisomy 21, the so 
called Down's syndrome. 
 
 
Sources used for the glossary 
http://ghr.nlm.nih.gov/ghr/glossary 
www.antenataltesting.info/glossary.html 
www.firstbabymall.com/expecting/pregnan
cy/testing2.htm 
www.medgen.ubc.ca/wrobinson/mosaic/glo
ssary.htm 
www.nature.ca/genome/02/022_mno_e.cfm 
www.paternityangel.com/general_info_zon
e/Glossary.htm 
www.tellparliament.net/scitech/glossary 
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www.todaysplanet.com/pg/beta/medical/glo
ssary.htm 
www.ucl.ac.uk/~ucbhjow/b241/glossary.ht
ml 
www.webmd.com/content/article/4/1680_5
1798 
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